A Trial for Minimally Invasive Neurosurgery With AI-assisted Robotic Guidance for Moderate Basal Ganglia Hemorrhage (RAINBOW-MBH)
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 330 people, planned
- Started
- 30 Sept 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Minimally invasive basal ganglion hematoma evacuation with Tract-based AI Robot Guiding System
- Patients will be managed with guideline-based medications
- Record updated
- 8 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Age ≥18 years at randomization
- Hypertensive basal ganglia hemorrhage confirmed by CT/CTA
- Hematoma volume 15-30 mL (excluding 30 mL)
- Functional impairment (aphasia, hemiparesis with strength ≤3, or NIHSS ≥15)
- CT shows stable hematoma (≥6h interval, change <5 mL)
- GCS ≥9
- Surgery feasible within 72h after onset
- Pre-ICH mRS ≤1
- Informed consent obtained according to laws and ethics
Who cannot take part
- Patients with severe concomitant diseases that may interfere with outcome assessment
- Radiologically diagnosed cerebrovascular abnormalities, as well as ischemic infarction converting to intracerebral hemorrhage, or recent (within 1 year) recurrence of intracerebral hemorrhage
- Any irreversible coagulopathy disorders or known coagulation system disease; platelet count <100,000; INR >1.4; use of anticoagulants within 7 days prior to this hemorrhage
- Hematoma involving the thalamus, midbrain, or other areas
- Signs of impending brain herniation, such as midline shift >1 cm or changes in the ipsilateral pupil
- Pregnant or possibly pregnant
- Poor compliance or follow-up difficulties
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Basal ganglia hemorrhage
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A nationwide, prospective, multicenter randomized controlled clinical trial to evaluate the therapeutic effects of the fiber tract-based artificial intelligence (AI) Robot Guiding System on the perioperative and long-term recovery of patients with moderate-volume basal ganglion hemorrhage.
The 2 groups in the trial
- Tract-based AI Robot Guiding System GroupTreatment being tested
Patients will be operated on minimally invasive puncture and aspiration using Tract-based AI Robot guidance System
Treatment: Minimally invasive basal ganglion hematoma evacuation with Tract-based AI Robot Guiding System
- Conservative GroupSham treatment, for comparison
Patients will be managed with guideline-based medications without surgery
Treatment: Patients will be managed with guideline-based medications
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Moderate Basal Ganglia Hemorrhage (RAINBOW-MBH)
- Criteria questions
- Built from NCT06465719, who can take part
- Record updated
- 8 January 2026